공시 • Oct 14

Geron Corporation Announces Executive Leadership Transitions

Geron Corporation announced several executive transitions and appointments designed to align the company’s leadership structure with its strategic priorities. Andrew Grethlein, Ph.D. who joined Geron in September 2012 and has served as Executive Vice President, Chief Operating Officer since January 2019, will depart the company on October 15, 2025, transitioning to a consulting role, while pursuing other interests. Jim Ziegler, who joined the company in September 2024 as Executive Vice President, Chief Commercial Officer, will also depart on October 15, 2025, to pursue other interests. Succeeding Jim, Ahmed ElNawawi (“Nawawi”) has been appointed Executive Vice President, Chief Commercial Officer, effective October 20, 2025. In this role, Nawawi will assume leadership of Geron’s commercial organization to advance the company’s strategic priorities—driving growth, maximizing the potential of RYTELO (imetelstat), and strengthening the foundation for potential future portfolio expansion. In addition to Nawawi’s appointment, Geron announced the appointment of three other seasoned executives to its leadership team: Shanthakumar (“Shantha”) Tyavanagimatt as Senior Vice President, Chief Technical Officer; Dawn Schottlandt as Senior Vice President, Investor Relations and Corporate Affairs; and Bryan Ridgell as Senior Vice President, Portfolio and Project Management and Chief of Staff. Together, these leaders bring deep experience across technical operations, investor relations and corporate affairs, and portfolio management, further strengthening the company’s commercial, operational and development capabilities. Nawawi most recently served as Senior Vice President and U.S. Commercial Head at Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, where he led the U.S. commercial organization spanning the sales, marketing, market access, commercial excellence, and data analytics functions. During his tenure, he successfully built the U.S. business from the ground up—expanding the team from 30 to 165 employees and delivering three consecutive years of topline and bottom-line growth. He oversaw the U.S. launch of ORSERDU in metastatic breast cancer, which was recently recognized as one of the top oncology launches in recent years, as well as drove renewed growth for ELZONRIS in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Before joining Stemline, Nawawi spent nearly two decades at Novartis Oncology in global, regional, and country leadership roles across the U.S., Europe, and the Middle East. His experience includes leading country P&L organizations, launching multiple oncology and hematology brands, and driving cultural and organizational transformation. He received an MBA from the University of Leicester and a B.S. in Clinical Pharmacy from Ain Shams University in Cairo, Egypt. Additional information on the other new executives and the experience they bring to Geron follows: Shantha Tyavanagimatt, Senior Vice President, Chief Technical Officer, brings more than 25 years of global leadership across drug development, CMC, and technical operations. He has advanced oncology and antiviral programs from early development through global approval and commercialization, with a proven record of building high-performing teams and forging strong partnerships to deliver transformative therapies to patients. He most recently served as Senior Vice President of Technical Operations at IDEAYA Biosciences, leading global CMC and supply-chain strategies and driving technical excellence, scalability and “right-first-time” regulatory approvals that enabled reliable access to new medicines. Prior to that, as Senior Vice President of Global Pharmaceutical Operations & Early Development at CTI BioPharma, he guided the company through multiple NDA and MAA approvals and established a resilient global supply network. Mr. Tyavanagimatt is expected to join Geron on October 20, 2025. Dawn Schottlandt, Senior Vice President, Investor Relations and Corporate Affairs, brings more than 20 years of experience in investor relations and corporate affairs within the life sciences industry. She has supported both private and public companies through IPOs, regulatory approvals, acquisitions, and major data milestones, building programs that strengthen visibility and engagement with the investment community. She most recently served as Managing Director at Argot Partners, leading investor relations strategy for a portfolio of biotechnology clients. Ms. Schottlandt is expected to join Geron on October 20, 2025. Bryan Ridgell, Senior Vice President, Portfolio and Project Management and Chief of Staff, brings more than 20 years of experience in program and portfolio management within the biotechnology industry. He has led global cross-functional teams across R&D, regulatory affairs, manufacturing, and clinical operations to drive alignment with key development objectives. He previously served as Senior Vice President, Portfolio and Project Management at GlycoMimetics, where he was a member of the Executive Leadership Team and partner to the CEO in portfolio planning, resource optimization, and execution of late-stage clinical programs. Mr. Ridgell joined Geron on October 13, 2025.

공시 • Dec 11

+ 1 more update

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

Geron Corporation announced new analyses presented at the 66thAmerican Society of Hematology (ASH) Annual Meeting from the IMerge clinical trial in patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia suggesting clinical activity of first-in-class telomerase inhibitor RYTELO™ (imetelstat) regardless of type or number of prior therapies, as well as favorable patient-reported outcomes (PROs). This oral presentation reported findings from analyses investigating the effects of prior therapies on the clinical activity of imetelstat using pooled data from IMerge Phase 2, Phase 3, and the QTc substudy. Of the 226 total imetelstat-treated LR-MDS patients included in this analysis, 90% had prior treatment with an erythropoiesis-stimulating agent (ESA), 12% had prior treatment with lenalidomide, 16% had prior treatment with luspatercept and 10% had prior treatment with a hypomethylating agent (HMA). Across this pooled population, median imetelstat treatment duration was 33.6 weeks (range: 0.1-260.1 weeks). Imetelstat clinical activity was observed in the pooled patient population consistent with that of the IMerge Phase 3 pivotal trial with regards to safety and critical efficacy measures that include =8-week red blood cell transfusion independence (RBC-TI), =24-week RBC-TI, RBC transfusion reduction =4 U/8 weeks and hemoglobin rise =1.5 g/dL/8 weeks. The results suggest that patients who were ESA ineligible, patients who had prior treatment with luspatercept or lenalidomide, or patients who had prior treatment with ESAs followed by luspatercept or lenalidomide experienced clinical benefit from imetelstat treatment similar to that demonstrated in the IMerge Phase 3 pivotal trial. Patients who had prior treatment with HMAs, or with ESAs followed by HMAs, showed modest clinical activity with imetelstat. Overall, while these analyses were limited by the small number of patients in each group, imetelstat showed clinical activity regardless of prior ESA response status and regardless of the number of prior lines of therapy. This poster presentation reports initial results from the ventricular repolarization (QTc) substudy of IMerge conducted per FDA guidance. This substudy differed from the IMerge Phase 3 trial in its crossover design, the inclusion of patients with del(5q) MDS, and by allowing prior lenalidomide and HMA therapy besides ESAs. The QTc substudy population comprised 53 treated patients (n=35 imetelstat, n=18 placebo). As of the data cutoff on May 10, 2024, 16 of 18 placebo recipients crossed over to receive imetelstat. Median treatment duration on imetelstat, including crossover (n=51) was 29.3 weeks; median duration in the imetelstat group (n=35) was 37.0 weeks and median duration in the crossover group (n=16) was 27.9 weeks. In the total imetelstat population (n=51), 41% of patients (n=21) achieved =8-week RBC-TI, 25% of patients (n=13) achieved =24-week RBC-TI, 41% of patients (n=21) achieved hematologic improvement-erythroid (HI-E) per IWG 2018 criteria, 35% of patients (n=18) had hemoglobin rises =1.5 g/dL lasting =8 weeks and 75% of patients (n=38) had RBC transfusion reductions =4 U/8 weeks. In patients with prior luspatercept, lenalidomide or HMA (azacitidine or decitabine) treatment, 30% (7/23), 38% (5/13), and 21% (3/14) of patients achieved =8-week RBC-TI, and 22% (5/23) 15% (2/13), and 14% (2/14) achieved =24-week RBC-TI, respectively. Patients treated with imetelstat showed no treatment-related changes in absolute and change in QTcF nor clinically meaningful effects on cardiac repolarization compared with placebo. The poster concludes that in this QTc substudy, imetelstat was associated with an absence of proarrhythmic risk, durable RBC-TI, transfusion reduction, clinically meaningful increases in hemoglobin, and a safety profile comparable to the overall population of the pivotal Phase 3 IMerge trial. RBC-TI was attained in imetelstat-treated patients who received prior therapies with HMA, luspatercept and lenalidomide, supporting the use of imetelstat in patients with relapsed or refractory LR-MDS regardless of prior therapies. This poster reports on the exploratory PRO analysis from IMerge Phase 3, with a data cutoff of October 2022. PROs were assessed with validated using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), Functional Assessment of Cancer Therapy-Anemia (FACT-An), and Quality of Life in Myelodysplasia Scale (QUALMS) questionnaires. Sustained meaningful improvement in fatigue was defined as a =3-point increase in FACIT-Fatigue score for =2 consecutive assessments. The PRO population (n=175) included all patients in the intent-to-treat population who had FACIT-Fatigue data at baseline and consisted of 118 imetelstat-treated patients and 57 patients who received placebo. In the subgroup analysis, more patients treated with imetelstat than placebo reported sustained improvement in fatigue regardless of ring sideroblast (RS) status, prior transfusion burden and baseline serum EPO levels. Additionally, improvement in fatigue was seen in more patients who responded to imetelstat versus those who did not across measures of response including RBC-TI, hemoglobin rise and transfusion reduction. The QUALMS and FACT-An analyses suggested that imetelstat maintained QOL and anemia symptoms, while placebo recipients experienced worsening QOL and anemia symptoms. The poster concludes that data from the pivotal IMerge phase 3 trial showed that improvement in fatigue with imetelstat was associated with reduced transfusion burden and a rise in hemoglobin and that imetelstat appears to offer the advantage of sustained RBC-TI benefit while maintaining QOL in patients with LR-MDS with TD anemia.

총 주주 수익률	-0.5%
미래 배당 수익률	n/a
배당 성장률	n/a
다음 배당 지급일	n/a
배당락일	n/a
주당 배당금	n/a
배당 성향	n/a

구분	배당 수익률
회사 (GERN)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Biotechs)	2.4%
분석가 예측 (GERN) (최대 3년)	n/a

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/14 00:01
종가	2026/05/14 00:00
수익	2026/03/31
연간 수익	2025/12/31

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

분석가	기관
Douglas Buchanan	Brean Capital Historical (Janney Montgomery)
Thomas Shrader	BTIG
Charles Duncan	Citizens JMP Securities, LLC

Geron 배당 및 자사주 매입

배당 기준 점검 0/6

핵심 정보

최근 배당 및 자사주 매입 업데이트

Recent updates

Geron Corporation Presents First Real-World Evidence Study of Rytelo (Imetelstat) in Lower-Risk Myelodysplastic Syndromes

Geron Sees Q1 Growth as RYTELO Revenue Accelerates and Clinical Milestones Approach

Geron Corporation Reiterates Financial Guidance for 2026

GERN: At The Market Offering Will Support Refined Earnings Outlook

Price target increased by 11% to US$4.00

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

GERN: Refined Risk And Earnings Assumptions Will Support Upside Through 2026

Geron Corporation to Report Q1, 2026 Results on May 06, 2026

Geron Corporation Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary

Geron Corporation, Annual General Meeting, May 20, 2026

GERN: Future Myeloid Franchise And 2026 Outlook Will Drive Upside

New minor risk - Share price stability

Geron Corporation Announces the Appointment of Patricia S. Andrews and Constantine Chinoporos to Board of Directors

GERN: Future Myeloid Franchise And 2026 Revenue Guidance Will Support Upside

Geron: Minimal Sales Growth But A Potential Run-Up Ahead

GERN: Future Profit Upside Will Be Supported By Conservative Forecast Reset

Geron Corporation has filed a Follow-on Equity Offering in the amount of $150 million.

Full year 2025 earnings: EPS and revenues miss analyst expectations

GERN: Future Profit Expansion Will Be Driven By Margin Improvement Potential

Geron Corporation to Report Q4, 2025 Results on Feb 25, 2026

GERN: Future Myeloid Franchise And 2026 Guidance Will Drive Upside

Geron Corporation's (NASDAQ:GERN) Prospects Need A Boost To Lift Shares

GERN: Future Myeloid Franchise Progress Will Drive Upside Potential

Geron Corporation Provides Earnings Guidance for 2026

GERN: Future Myeloid Indications Will Drive Upside Despite Safety Trade Offs

GERN: Future Myeloid Malignancy Indications Will Drive Upside Despite Safety Risks

Geron (NASDAQ:GERN) Is Using Debt Safely

GERN: Expanded Blood Cancer Indications Will Drive Upside Despite Safety Concerns

Geron Corporation Presents New Data At Ash 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of Rytelo®? (Imetelstat) in Lower-Risk Mds

GERN: Future Profit Expansion Will Drive Bullish Share Price Outlook

Price target decreased by 8.0% to US$3.33

GERN: Stronger Profit Margins Will Drive Share Price Momentum Ahead

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Geron Corporation's (NASDAQ:GERN) Business And Shares Still Trailing The Industry

Geron Corporation to Report Q3, 2025 Results on Nov 05, 2025

Insufficient new directors

Geron Corporation Announces Board of Director Departures, Effective October 10, 2025

Geron Corporation Announces Executive Leadership Transitions

Aging Population Trends Will Expand Hematology Market Opportunity

New minor risk - Share price stability

Here's Why Geron (NASDAQ:GERN) Can Manage Its Debt Despite Losing Money

Second quarter 2025 earnings released

Geron Corporation Announces Chief Executive Officer Changes,Effective August 7, 2025

Geron Corporation to Report Q2, 2025 Results on Aug 06, 2025

Geron Corporation(NasdaqGS:GERN) dropped from Russell 3000 Value Index

Geron Corporation's (NASDAQ:GERN) Shares Climb 30% But Its Business Is Yet to Catch Up

Geron Corporation Announces Presentations At ASCO and EHA Underscoring RYTELO®? Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelibrosis Program

Consensus revenue estimates fall by 11%

Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results

Forecast breakeven date pushed back to 2027

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates fall by 15%

EU Approval And US Initiatives Will Expand Future Markets

Is Geron (NASDAQ:GERN) A Risky Investment?

Geron Corporation, Annual General Meeting, May 21, 2025

Geron Corporation to Report Q1, 2025 Results on May 07, 2025

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Pomerantz Law Firm Announces the Filing of a Class Action against Geron Corporation

Geron Corp: How Concerned Should We Be About Rytelo Sales?

Levi & Korsinsky, LLP Files a Complaint to Recover Losses Suffered by Purchasers of Geron Corporation Securities

Geron Corporation Announces Chief Executive Officer Changes

Risks Still Elevated At These Prices As Geron Corporation (NASDAQ:GERN) Shares Dive 45%

Executive VP & Chief Commercial Officer recently bought US$160k worth of stock

New minor risk - Shareholder dilution

We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely

New minor risk - Share price stability

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales

Geron Corporation to Report Q4, 2024 Results on Feb 26, 2025

Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch

Consensus revenue estimates decrease by 17%, EPS upgraded

Price target increased by 9.9% to US$7.88

Geron Corporation Provides Revenue from U.S. Sales of RYTELO Guidance for the Fourth Quarter Ended December 31, 2024

Geron Corporation Announces Positive CHMP Opinion for RYTELO (Ietelstat) for the Treatment of Adults with Transfusion-Dependent Anemia Due to Lower-Risk MDS

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies